With lat­est Keytru­da OK, Mer­ck edges in­to Glax­o­SmithK­line’s (small) PD-1 turf

Mer­ck has col­lect­ed an­oth­er ap­proval for flag­ship PD-1 in­hibitor Keytru­da and, in do­ing so, ven­tured deep­er in­to a rel­a­tive­ly new bio­mark­er.

The ex­pand­ed OK cov­ers the use of Keytru­da in pa­tients with ad­vanced en­dome­tri­al car­ci­no­ma that can be clas­si­fied as mi­crosatel­lite in­sta­bil­i­ty-high (MSI-H) or mis­match re­pair de­fi­cient (dMMR), as de­ter­mined by an FDA-ap­proved test. These pa­tients would al­so have pro­gressed fol­low­ing sys­temic ther­a­py and are not can­di­dates for cu­ra­tive surgery or ra­di­a­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER